Maintenance therapy for advanced bile duct or gallbladder cancer
Part of Cancer clinical trials.
This study tests whether giving a vaccine-like treatment (OBI-833/OBI-821) after initial chemotherapy can help keep bile duct or gallbladder cancer from growing. If you have a tumor that is stable or improved after gemcitabine and cisplatin, this maintenance therapy might offer a new way to control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 20 years old.
- You must have a bile duct or gallbladder cancer that is advanced or has spread and cannot be removed by surgery.
- Your cancer must have been treated with gemcitabine and cisplatin for about 3 months, and it should be stable or have shrunk.
- Your tumor must have a specific marker called Globo H, and the level must be high enough (as tested in a lab).
- You must be able to care for yourself (ECOG score 0 or 1) and have a life expectancy of at least 6 months.
- You must not have HIV, active hepatitis B or C, or conditions requiring steroids or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether continuing an immunotherapy drug (durvalumab or pembrolizumab) alone after initial chemo-immunotherapy is safe and effective for people with advanced bile duct or gallbladder cancer. The goal is to see if this maintenance approach helps keep the cancer from growing.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.